Search Results

Get ready to stay up-to-date with the latest research, advancements, and news in the field. From the scientist’s view: a conversation with … Chris Tate AI is dreaming up drugs that no one has ever

surprising discovery that β-arrestin can bind GPCRs without receptor activation, to visualizing intermediate states the Symposia GPCR Publication Highlights     Arrestin recognizes GPCRs independently of the receptor state Triple Labeling Resolves a GPCR Intermediate State by Using Three-Color Single Molecule FRET .   A powerful three-color approach captures dynamic receptor states in real time. Whether you're decoding a hidden receptor state or hunting for the next orphan GPCR ligand, we're here

  ✅ Avoid costly errors:  Master vital models to confidently forecast outcomes, before it’s too late

Chris Tate About this episode Dr. Chris Tate obtained his Ph.D. from the University of Bristol in 1989 and then moved to the University Chris also worked on the E. coli multidrug transporter EmrE and obtained both 2D and 3D crystals as well Join me to learn more about Chris’s work and his role in founding Heptares which was later acquired by Chris Tate on the web LinkedIn ResearchGate Pubmed Google Scholar Sosei Heptares Wikipedia MRC Laboratory

Chris Tate and Dr. Richard Henderson at the Laboratory of Molecular Biology in Cambridge, UK. help us understand your needs to bring you exciting and informative content; this short survey should take

GPCR Podcast << Back to podcast list Strategic Partners Chris Langmead Chris Langmead is Professor, Deputy in drug discovery, particularly in the field of psychiatry, where he has led multiple projects into late Prior to joining Heptares, Chris was a neuroscience researcher at GlaxoSmithKline, UK (1998-2009). Chris serves on the editorial boards of the British Journal of Pharmacology, ACS Chemical Neuroscience help us understand your needs to bring you exciting and informative content; this short survey should take